Lung Cancer Vaccines: Pipeline, Strategies and Clinical

Report Summary

This report provides a comprehensive review of 42 candidate vaccines that are being evaluated for the treatment of lung cancer, covering pipeline, disease-targeting strategies and clinical findings. These vaccines are directed at 24 antigens or antigen combinations.

Globally, lung cancer is the most common cancer and in 2008 there were an estimated 1.6 million new cases and 1.4 million deaths (almost 20% of all cancer deaths) caused by this disease. Five-year survival rates are also low (15-20%) compared to other common cancers. In the US, studies have shown that lung cancer-care costs (in 2006) were the third highest of all cancers, while indirect costs (2005) were higher than for any other cancer.

Patient needs and the high burden of lung cancer drive the development of new therapies. While improvements have been seen in diagnosis and treatments (surgery, radiotherapy, chemotherapy and targeted drugs), new therapies that build on the capabilities of existing approaches, are urgently required. Today, developments continue to be made in drug treatments for lung cancer; in chemotherapy, new drug combinations and targeted molecules. In particular, advances are being seen in the field of immunotherapy; in the development of new therapeutic antibodies and therapeutic vaccines.

This Report

This report (see brochure) provides a comprehensive review of lung cancer vaccines and reviews R&D and clinical developments in the treatment of lung cancer as the primary indication, as well as studies that are evaluating lung cancer alongside other cancers.

Today, more than 40 candidate lung cancer vaccines are in development or being evaluated for the treatment of lung cancer, most of which are already in clinical trials. This field is also showing substantial innovation and 24 different antigen/multiple antigen targeting strategies are being investigated. For the purpose of this report, multiple antigen targeting approaches have been treated as single strategies. This report gives an overview of the status and clinical findings of these candidate vaccines, and gives developmental and market-related perspectives in this rapidly developing field.

Key content:

• Late-stage (Phases 2/3, 3 and Approved, n = 5) pipeline vaccines and companies
• Early-stage (Preclinical and Phases 1, 1/2 and 2, n= 37) pipeline vaccines and companies
• Other (mainly antibody related, n=6) candidate therapies in the development pipeline for targeting lung cancer, Phase 1, 1/2 and 2
• Antigens/antigen combinations being targeted by vaccines from preclinical through to Phase 3 and Approved
• Descriptions of clinical trials (patients and numbers, conditions, treatments, regimens, Phase 1-3) of therapeutic vaccines being evaluated for the treatment of lung cancer
• Summaries of clinical status and clinical findings (safety, adverse events and multiple event-related clinical responses) reported following clinical trials (Phase 1-3) of vaccines being evaluated for the treatment of lung cancer
• Commercial partnerships and collaborations on pipeline therapeutic vaccines
• Drug combination strategies in the evaluation of therapeutic vaccines for the targeting of lung cancer
• A comprehensive listing of salient details of clinical trials of therapeutic vaccines being evaluated for the treatment of lung cancer
• Technical and market insights and perspectives in the development and clinical evaluation of therapeutic vaccines for the treatment of lung cancer
• Competitive and market-related information

Table Of Contents

Executive Summary

Chapter 1 Background
Summary
1 Lung Cancer
1.1 Statistics
1.2 Diagnosis
1.3 Lung Cancer Staging
1.4 Treatment of Lung Cancer
1.5 Survival Rates
1.6 Cost of Lung Cancer
1.7 New Developments
1.8 This Report
References

Chapter 2 Approved and Late-Stage Vaccines
Summary
2.1 Introduction
2.2 Overview
2.3 (One vaccine, Approved)
2.4 – 2.6 (Three vaccines, Phase 3)
2.7 (One vaccine, Phase 2/3)
References

Chapter 3 Early-Stage Vaccines
Summary
3.1 Introduction
3.2 Overview
3.3 – 3.12 (Ten vaccines, Phase 2)
3.13 – 3.22 (Ten vaccines, Phase 1/2)
3.23 – 3.37 (Fifteen vaccines, Phase 1)
3.38 – 3.39 (Two Vaccines, Preclinical)
References

Chapter 4 Other Candidate Therapies
Summary
4.1 Introduction
4.2 Overview
4.3 (One Immune Activator, Phase 2)
4.4 (One Antibody Conjugate, Phase 1/2)
4.5 (One Bispecific Antibody, Phase 1)
4.6 (One Antibody Conjugate, Phase 1)
4.7 (One Immune Stimulant, Phase 1)
4.8 (One Antibody Conjugate, Phase 1)
References

Chapter 5 Discussion
Summary
5.1 Background
5.2 Pipeline
5.3 Vaccines
5.4 Other Candidate Therapies
5.5 Companies
5.6 Therapeutic Targets
5.7 Therapeutic Approaches
5.8 Conditions
5.9 Market Perspectives
References

List of Tables

Global incidence and mortality from lung cancer, 2008
NSCLC survival rates, according to cancer stage
1.3a Five-year relative cancer survival rates in the USA for white males
1.3b Five-year relative cancer survival rates in the USA for white females
US national expenditure on different cancers (2006)
US lost productivity due to different cancer types in the US, 2005
2.1 Approved/late-stage vaccines for the treatment of lung cancer
3.1 Early-stage vaccines being developed or evaluated for the treatment of lung cancer or lung cancer/other cancers
4.1 Other (largely antibody-related) therapies being developed or evaluated for the treatment of lung cancer or lung cancer/other cancers
5.1 Approved/late-stage candidate vaccines being developed for the treatment of lung cancer
5.2 Early-stage candidate vaccines being developed or evaluated for lung cancer or for lung/other cancers
Other (primarily antibody-related) therapies in development or being evaluated for lung cancer or for lung cancer/other cancers
Approved/candidate vaccines for the treatment of lung cancer or for lung cancer/other cancers
Other candidate therapies (primarily antibody-related) for the treatment of lung cancer or for lung cancer/other cancers
NSCLC survival rates, according to cancer stage

List of Figures

3.1 Early-staged pipeline vaccines for the treatment of lung cancer or lung cancer/other cancers
5.1 Early-stage pipeline vaccines in development or being evaluated for lung cancer or for lung/other cancers
5.2 Other (primarily antibody-related) early-stage candidate therapies in development or being evaluated for lung cancer or for lung cancer/other cancers
5.3 Organisations developing or evaluating lung cancer therapeutic vaccines
5.4 Clinical trials of vaccines for the treatment of lung cancer or lung cancer/other cancers, involving single or combination agents